BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25600432)

  • 1. The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence.
    Leunissen TC; De Borst GJ; Janssen PW; ten Berg JM
    J Cardiovasc Surg (Torino); 2015 Apr; 56(2):165-75. PubMed ID: 25600432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet function testing and tailored antiplatelet therapy.
    Janssen PW; ten Berg JM
    J Cardiovasc Transl Res; 2013 Jun; 6(3):316-28. PubMed ID: 23543615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
    Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study.
    Mangiacapra F; Patti G; Barbato E; Peace AJ; Ricottini E; Vizzi V; Gatto L; D'Ambrosio A; De Bruyne B; Wijns W; Di Sciascio G
    JACC Cardiovasc Interv; 2012 Mar; 5(3):281-9. PubMed ID: 22440493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    Thromb Haemost; 2015 Jan; 113(1):37-52. PubMed ID: 25231675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-institutional patterns of clopidogrel response among patients undergoing transcarotid artery revascularization.
    Rokosh RS; Rockman C; Garg K; Wang SK; Motaganahalli RL; Schroeder AC; Sobraske PJ; Stoner MC; Tarbunou YA; Marmor RA; Malas MB; Maldonado TS
    Vascular; 2024 Jun; 32(3):558-564. PubMed ID: 36428145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of clopidogrel.
    Sarafoff N; Byrne RA; Sibbing D
    Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet effects of clopidogrel dose adjustment (75 mg/d vs 150 mg/d) after carotid stenting.
    González A; Moniche F; Cayuela A; Gonzalez-Marcos JR; Mayol A; Montaner J
    J Vasc Surg; 2014 Aug; 60(2):428-35. PubMed ID: 24629989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Orban M; Mayer K; Morath T; Bernlochner I; Hadamitzky M; Braun S; Schulz S; Hoppmann P; Hausleiter J; Tiroch K; Mehilli J; Schunkert H; Massberg S; Laugwitz KL; Sibbing D; Kastrati A
    Thromb Haemost; 2014 Dec; 112(6):1190-7. PubMed ID: 25183544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anti-platelet agents: the end of resistance?
    Kastrati A
    Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
    Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H
    J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
    Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA;
    J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L
    Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
    Cayla G; Collet JP; Silvain J; Montalescot G
    Arch Cardiovasc Dis; 2014 Jan; 107(1):1-3. PubMed ID: 24332911
    [No Abstract]   [Full Text] [Related]  

  • 20. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
    Trenk D; Kristensen SD; Hochholzer W; Neumann FJ
    Thromb Haemost; 2013 May; 109(5):834-45. PubMed ID: 23238773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.